JAMES R. MCARTHUR, M.D.; JOHN W. ATHENS, M.D., F.A.C.P.; MAXWELL M. WINTROBE, M.D., Ph.D., F.A.C.P.; GEORGE E. CARTWRIGHT, M.D., F.A.C.P.
Sixty-seven patients with symptomatic multiple myeloma were studied. Thirty-nine were treated with melphalan. The initial dose of 4 mg by mouth daily was reduced if the white blood count fell below 2,000 to 2,500/mm3. There were significant objective and subjective improvement and increased survival in the melphalan-treated patients as compared with a retrospective control group of 28 patients. The results compare favorably with reported series in which high-dose intermittent regimens were used. Information is insufficient to compare toxicity and complications associated with the two regimens.
MCARTHUR JR, ATHENS JW, WINTROBE MM, CARTWRIGHT GE. Melphalan and Myeloma: Experience with a Low-Dose Continuous Regimen. Ann Intern Med. ;72:665–670. doi: 10.7326/0003-4819-72-5-665
Download citation file:
Published: Ann Intern Med. 1970;72(5):665-670.
Hematology/Oncology, Multiple Myeloma.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use